Forte Biosciences (NASDAQ: FBRX) set for Nasdaq delisting

Rhea-AI Filing Summary

Forte Biosciences, Inc. (FBRX) is having its common stock removed from listing and/or registration on the Nasdaq Stock Market LLC under Section 12(b) of the Securities Exchange Act of 1934, as notified on Form 25. Nasdaq states it has complied with its rules under 17 CFR 240.12d2-2(b), and the issuer has complied with exchange rules and 17 CFR 240.12d2-2(c) governing voluntary withdrawal.

Filing Explained

The filing puts Forte’s common stock into a Nasdaq delisting and Section 12(b) withdrawal process; it does not establish that the change is complete.

Nasdaq submitted a Form 25 notifying the SEC that Forte Biosciences’ common stock is being removed from Nasdaq and its Section 12(b) registration withdrawn; the filing records the removal action without stating that it is already complete.

The company’s stated mechanics are compliance with Nasdaq requirements for a voluntary withdrawal, so the structural change concerns the stock’s exchange listing and registration status.

Key Terms

Form 25, Section 12(b) of the Securities Exchange Act of 1934, 17 CFR 240.12d2-2(b), 17 CFR 240.12d2-2(c)

4 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) of the Securities Exchange Act of 1934 regulatory

"REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934"

17 CFR 240.12d2-2(b) regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

17 CFR 240.12d2-2(c) regulatory

"the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal"

FAQ

What action is being taken regarding Forte Biosciences, Inc. (FBRX) stock?

The Nasdaq Stock Market LLC filed a Form 25 to remove Forte Biosciences, Inc. common stock from listing and/or registration under Section 12(b) of the Securities Exchange Act of 1934, indicating compliance with its own rules and SEC Rule 12d2-2.

Which class of Forte Biosciences (FBRX) securities is affected?

The filing covers Forte Biosciences, Inc. Common Stock. Nasdaq is striking this class of securities from listing and/or withdrawing registration on the exchange pursuant to SEC Rule 12d2-2.

Which rules govern the FBRX delisting and deregistration action?

The action is taken under 17 CFR 240.12d2-2, including subsections (a)(1)-(4), with Nasdaq certifying compliance under 12d2-2(b) and the issuer complying with exchange rules and 12d2-2(c) for voluntary withdrawal from listing and registration.

Who filed the Form 25 for Forte Biosciences, Inc. (FBRX)?

The Nasdaq Stock Market LLC filed the Form 25 for Forte Biosciences, Inc. It was signed on Nasdaq’s behalf by Tara Petta, identified as an AVP, who certified reasonable grounds for filing the Form 25.

What is the Commission File Number for Forte Biosciences, Inc. on this Form 25?

The Commission File Number associated with Forte Biosciences, Inc. on this Form 25 is 001-38052, identifying the company’s registration under Section 12(b) of the Securities Exchange Act of 1934 that is being removed from listing and/or registration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/27/2026 - 09:06 AM Accepted by SEC EDGAR 08/27/2026 - 09:06 AM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38052

Issuer:	Forte Biosciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	3060 Pegasus Park Dr., Building 6
	Dallas	TEXAS	75247
Telephone number:					(310) 618-6994

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-08-27	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.